prikaz prve stranice dokumenta Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party
  Download
PDF 386.56 KB
Scientific paper - Original scientific paper
Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party
Journal for ImmunoTherapy of Cancer, 11 (2023), 4; e006406. https://doi.org/10.1136/jitc-2022-006406
Penack, Olaf; Peczynski, Christophe; Koenecke, Christian; Polge, Emmanuelle; Kuhnl, Andrea; Fegueux, Nathalie; Daskalakis, Michael; Kröger, Nicolaus; Dreger, Peter; Besley, Caroline; Schanz, Urs; Bloor, Adrian; Ganser, Arnold; Forcade, Edouard; Corral, Lucia López; Passweg, Jakob R; Novak, Urban; Moiseev, Ivan; Schoemans, Hélène; Basak, Grzegorz W; Chabannon, Christian; Sureda, Anna; Averbuch, Dina; Glass, Bertram; de la Camara, Rafael; Perić, Zinaida More authors...

Cite this document

Penack, O., Peczynski, C., Koenecke, C., Polge, E., Kuhnl, A., Fegueux, N. ... Perić, Z. (2023). Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party. Journal for ImmunoTherapy of Cancer, 11. (4). doi: 10.1136/jitc-2022-006406

Penack, Olaf, et al. "Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party." Journal for ImmunoTherapy of Cancer, vol. 11, no. 4, 2023. https://doi.org/10.1136/jitc-2022-006406

Penack, Olaf, Christophe Peczynski, Christian Koenecke, Emmanuelle Polge, Andrea Kuhnl, Nathalie Fegueux, Michael Daskalakis, et al. "Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party." Journal for ImmunoTherapy of Cancer 11, no. 4 (2023). https://doi.org/10.1136/jitc-2022-006406

Penack, O., et al. (2023) 'Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party', Journal for ImmunoTherapy of Cancer, 11(4). doi: 10.1136/jitc-2022-006406

Penack O, Peczynski C, Koenecke C, Polge E, Kuhnl A, Fegueux N, and sur.. Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party. Journal for ImmunoTherapy of Cancer [Internet]. 2023 April [cited 2024 August 18];11(4). doi: 10.1136/jitc-2022-006406

O. Penack, et al., "Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party", Journal for ImmunoTherapy of Cancer, vol. 11, no. 4, April 2023. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:867008. [Accessed: 18 August 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party
AuthorOlaf Penack
AuthorChristophe Peczynski
AuthorChristian Koenecke
AuthorEmmanuelle Polge
AuthorAndrea Kuhnl
AuthorNathalie Fegueux
AuthorMichael Daskalakis
AuthorNicolaus Kröger
AuthorPeter Dreger
AuthorCaroline Besley
AuthorUrs Schanz
AuthorAdrian Bloor
AuthorArnold Ganser
AuthorEdouard Forcade
AuthorLucia López Corral
AuthorJakob R Passweg
AuthorUrban Novak
AuthorIvan Moiseev
AuthorHélène Schoemans
AuthorGrzegorz W Basak
AuthorChristian Chabannon
AuthorAnna Sureda
AuthorDina Averbuch
AuthorBertram Glass
AuthorRafael de la Camara
AuthorZinaida Perić
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
We investigated the incidence and outcome of anti-CD19 chimeric antigen receptor (CAR) T-cells-associated Common Terminology Criteria for Adverse Events (CTCAE) ≥grade 3 cytopenia. In the EBMT CAR-T registry, we identified 398 adult patients with large B-cell lymphoma who had been treated with CAR-T-cells with axicel (62%) or tisacel (38%) before August 2021 and had cytopenia status documented for the first 100 days. Most patients had received two or three previous lines of therapy, however, 22.3% had received four or more. Disease status was progressive in 80.4%, stable in 5.0% and partial/complete remission in 14.6%. 25.9% of the patients had received a transplantation before. Median age was 61.4 years (min–max; IQR=18.7–81; (52.9–69.5)). The cumulative incidence of ≥grade 3 cytopenia was 9.0% at 30 days (95% CI (6.5 to 12.1)) and 12.1% at 100 days after CAR T-cell infusion (95% CI (9.1 to 15.5)). The median time from CAR-T infusion to cytopenia onset was 16.5 days (min–max; IQR=1–90; (4–29.8)). Grade 3 and grade 4 CTCAE cytopenia occurred in 15.2% and 84.8%, respectively. In 47.6% there was no resolution. Severe cytopenia had no significant impact on overall survival (OS) (HR 1.13 (95% CI 0.74 to 1.73), p=0.57). However, patients with severe cytopenia had a poorer progression-free survival (PFS) (HR 1.54 (95% CI 1.07 to 2.22), p=0.02) and a higher relapse incidence (HR 1.52 (95% CI 1.04 to 2.23), p=0.03). In those patients who developed severe cytopenia during the first 100 days (n=47), OS, PFS, relapse incidence and non-relapse mortality at 12 months after diagnosis of severe cytopenia were 53.6% (95% CI (40.3 to 71.2)), 20% (95% CI (10.4 to 38.6)), 73.5% (95% CI (55.2 to 85.2)) and 6.5% (95% CI (1.7 to 16.2)), respectively. In multivariate analysis of severe cytopenia risk factors, only year of CAR-T infusion (HR=0.61, 95% CI (0.39 to 0.95), p=0.028) and total number of treatment lines before CAR-T infusion (one or two lines vs three or more, HR=0.41, 95% CI (0.21 to 0.83), p=0.013) had a significant positive association with the incidence of cytopenia. Other factors, such as previous transplantation, disease status at time of CAR-T, patient age and patient sex, had no significant association. Our data provide insight on frequency and clinical relevance of severe cytopenia after CAR T-cell therapy in the European real-world setting.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleJournal for ImmunoTherapy of Cancer
Numberingvol. 11, no. 4, e006406
e-ISSN2051-1426
DOIhttps://doi.org/10.1136/jitc-2022-006406
URN:NBNurn:nbn:hr:105:867008
Publication2023-04
Document URLhttps://jitc.bmj.com/lookup/doi/10.1136/jitc-2022-006406
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) icon
Created on2023-11-24 10:49:21